Parkinson's disease is ready for precision medicine

CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

(2016) Ju-Hee Kang et al.   ACTA NEUROPATHOLOGICA

How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?

(2016) Tanya Simuni et al.   PARKINSONISM & RELATED DISORDERS

The NINDS Parkinson's disease biomarkers program

(2015) Liana S. Rosenthal et al.   MOVEMENT DISORDERS

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

(2015) Niels Kruse et al.   NEUROBIOLOGY OF AGING

Differential effects of severe vs mild GBA mutations on Parkinson disease

(2015) Z. Gan-Or et al.   NEUROLOGY

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel recruitment strategy to enrich forLRRK2mutation carriers

(2015) Tatiana Foroud et al.   Molecular Genetics & Genomic Medicine

Personalised cancer medicine

(2014) Sarah E. Jackson et al.   INTERNATIONAL JOURNAL OF CANCER

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease

(2009) Alberto Ascherio   ARCHIVES OF NEUROLOGY